The listing / About
About this CJC-1295 digest
What this listing is, what it is not, and how each entry is tagged to the published literature.
What Meds CJC-1295 is
Meds CJC-1295 lays the peer-reviewed CJC-1295 literature out the way a good catalog lays out its stock: each finding shelved, tagged to its study, and easy to scan side by side. It is a reading of the record, not a counter you buy from. No clinician staffs it, no one here is diagnosed or advised, and nothing is manufactured, stocked, or shipped.
The listing metaphor is load-bearing. The two forms of the molecule sit on separate channels so they are never conflated, and the gaps in the evidence are marked as plainly as the findings. The aim is a surface you can scan and compare — not a storefront, and not a consultation.
What the name means
The 'meds' in the domain is editorial framing — a medicinal-science register, the stance this publisher takes toward the literature. It is not a claim that the site dispenses, prescribes, or sells; there is no pharmacy here, no counter, and no prescriber.
CJC-1295 is an unapproved research chemical with no approved human indication [1], and the listing treats it as exactly that throughout: a molecule with a documented pharmacology and an undocumented long-term safety profile. Where the literature is precise, so is the entry; where it goes silent, the entry says so.
How the listing is built
Each entry is assembled from the published record: the human pharmacokinetic studies, the rat bioconjugate work, the enzymology behind the substitutions, and the recent class reviews [1][2][8][13]. Every quantitative claim carries a citation to a numbered source in the full reference list. Where a claim is mechanistic rather than trial-proven — the CJC-1295/ipamorelin synergy, for instance — the entry flags it as such [11].
No findings are invented, no doses are recommended, and no commercial brands are named. When the honest answer to a common question is 'the data does not exist,' that is the answer shelved here.